EstuaryBio

Charting a new course for patients with kidney disease.

[EstuaryBio @EstuaryBio]

Estuary Biotherapeutics is on a mission to make #ADPKD history through targeted gene therapies designed to address the disease’s underlying genetic cause.

Led by CEO Wayne Sackett and built on landmark discoveries from scientific co-founders Stefan Somlo, MD, and Michael Caplan, MD, PhD, at @YaleMed, we're launching with $103 million to advance our lead programs, EST-201 and EST-101, toward clinical proof of concept.

Watch our story and learn more at https://t.co/mYelZdf1qQ.
https://t.co/DgetqnA6GG